| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/08/2004 | WO2003003018A3 Method for identifying compounds for the therapy of aging of the cardiovascular system |
| 01/08/2004 | WO2003000859A3 G-protein coupled receptors |
| 01/08/2004 | WO2002099036A3 Inhibition of neurodegeneration |
| 01/08/2004 | WO2002092623A8 INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF |
| 01/08/2004 | WO2002091996A3 Methods for treating cancer |
| 01/08/2004 | WO2002080952A3 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| 01/08/2004 | WO2002079448A3 G-protein coupled receptors |
| 01/08/2004 | WO2002072780A3 Igf antagonist peptides |
| 01/08/2004 | WO2002059310A3 Polynucleotides encoding cellular transporters and methods of use thereof |
| 01/08/2004 | WO2002056864A3 Differential delivery of nitric oxide |
| 01/08/2004 | WO2002056745A3 Method of treating parkinson's disease |
| 01/08/2004 | WO2002053596A3 Antibodies to insulin-like growth factor i receptor |
| 01/08/2004 | WO2002053594A3 Inhibitors of memapsin 2 and use thereof |
| 01/08/2004 | WO2002046225A3 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 01/08/2004 | WO2002045737A3 Methods of treatment involving human mda-7 |
| 01/08/2004 | WO2002036202A3 Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid |
| 01/08/2004 | WO2001066123A3 Composition consisting of phy906 and chemotherapeutic agents |
| 01/08/2004 | US20040006782 Non-human mammal mutant for expression of the alpha6 subunit of the nicotinic acetylcholine receptor, and use for screening substances that can interact with said receptor |
| 01/08/2004 | US20040006780 VEGF-modulated genes and methods employing them |
| 01/08/2004 | US20040006208 Comprises three-dimensional structure of bound immunoglobulin complex; antiinflammatory/anticarcinogenic; viricides |
| 01/08/2004 | US20040006138 For therapy of chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans |
| 01/08/2004 | US20040006135 Combination treatment for depression and anxiety |
| 01/08/2004 | US20040006134 Antiandrogenic biphenyls |
| 01/08/2004 | US20040006133 Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | US20040006124 Administering compound that is a ryanodine receptor antagonist in pharmaceutically acceptable vehicle to inhibit or prevent nerve cell injury or death |
| 01/08/2004 | US20040006120 Administering to a patient in need of such weight loss or treatment an effective amount of an inverse agonist of histamine H3 receptors, with the proviso that inverse agonist is not thioperamide |
| 01/08/2004 | US20040006116 For therapy of non-insulin dependent diabetes mellitus |
| 01/08/2004 | US20040006115 2-Oxothiazolidine 4-carboxylic acid compounds for promoting desquamation of the skin |
| 01/08/2004 | US20040006111 Transmucosal delivery of proton pump inhibitors |
| 01/08/2004 | US20040006091 Therapeutic agents useful for treating or preventing pain |
| 01/08/2004 | US20040006087 Method of treating cancer using FPT inhibitors and antineoplastic agents |
| 01/08/2004 | US20040006086 For therapy of metabolic and eating disorders such as obesity and hyperphagia, diabetes |
| 01/08/2004 | US20040006073 Method of treating attention deficit hyperactivity disorder |
| 01/08/2004 | US20040006063 Dipeptide derivatives |
| 01/08/2004 | US20040006060 Inducing contraception by delivering to a female of child-bearing age a selective estrogen receptor modulator comprising cyclothiocarbamate derivative |
| 01/08/2004 | US20040006049 For therapy of prostatitis, benign prostate hyperplasia or prostate cancer |
| 01/08/2004 | US20040006048 For prophylaxis and therapy of illnesses in which lipidperoxidation has role, food, beverages, health |
| 01/08/2004 | US20040006042 Administering 5-fluorouracil, leucovorin and diaminopyrimidine compound for therapy of cancer |
| 01/08/2004 | US20040006035 For modulating HIV cell fusion activity in a cell |
| 01/08/2004 | US20040006028 Administering a therapeutically effective amount of a flavin N-oxide; exposing flavin N-oxide to an activator, such that activation of the flavin N- oxide results in damage to the DNA in cancer cells without damage to the DNA in normal cells |
| 01/08/2004 | US20040006007 Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides |
| 01/08/2004 | US20040006004 This invention concerns a method for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient, said method comprising administering to said patient an agent affecting the NPY Y2 |
| 01/08/2004 | US20040005712 Transforming B lymphocytes with Epstein-Barr virus, incubating transformed B lymphocytes with flavin N-oxide photosensitizer, adding non-toxic antioxidant, and exposing lymphocytes to activator such as photoradiation to activate photosensitizer |
| 01/08/2004 | US20040005689 Three dimensional model of acute myeloid leukemia protein (AML-1) comprising runt domain for treating and preventing diseases associated with chromosomal translocations; genetic mapping |
| 01/08/2004 | US20040005688 Comprises dishevelled associated kinase (DAK) protein for diagnosis, prevention and treatment of cell proliferative diseases |
| 01/08/2004 | US20040005666 Methods and reagents for modulating cholesterol levels |
| 01/08/2004 | US20040005648 PYK2 related products and methods |
| 01/08/2004 | US20040005630 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| 01/08/2004 | US20040005629 Natural ligand of orphan G protein coupled receptor GPR86 and methods of use |
| 01/08/2004 | US20040005581 Comprises nucleotide sequences coding vanilloid receptor-like receptor (VR4) for diagnosing and treating pain, inflammation, neurodegeneration, cardiovascular, cancer and urogenital diseases; drug screening |
| 01/08/2004 | US20040005550 Methods and compositions useful for targeting activated vitronectin receptor alphavbeta3 |
| 01/08/2004 | US20040005368 Enhancing lipolysis and the suppression of appetite are presented. Currently the preferred embodiment has these formulations as two separate compositions because of taste considerations. It is known that the two separate compositions |
| 01/08/2004 | US20040005358 Formulation is provided which is capable of releasing vasopeptidase inhibitor, preferably omapatrilat or gemopatrilat, in a manner to provide therapeutically effective NEP inhibitory activity and therapeutically effective ACE |
| 01/08/2004 | US20040005355 Synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, a heavily sulfated |
| 01/08/2004 | US20040005322 Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| 01/08/2004 | US20040005315 Administering an immunosuppressive agent that depletes T cells and anti-alpha beta T cell receptor antibodies, and implanting an allograft into the recipient. |
| 01/08/2004 | US20040005311 Including a core of lysine and bromelain and, optionally, including lycopene; can be used to alleviate dementia-related symptoms. |
| 01/08/2004 | US20040005306 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 01/08/2004 | US20040005304 Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
| 01/08/2004 | US20040005303 In vivo induction for enhanced function of isolated hepatocytes |
| 01/08/2004 | US20040005299 Method for producing pseudo islets |
| 01/08/2004 | DE10228081A1 Verfahren zum Nachweis einer gesteigerten Tumorsuszeptibilität A method for detecting an increased tumor susceptibility |
| 01/08/2004 | DE10227668A1 Arzneimittel zur Behandlung des systemic inflammatory response syndrome Drugs for the treatment of systemic inflammatory response syndrome |
| 01/08/2004 | DE10227511A1 Mittel zur medikamentösen Behandlung von akuten und chronischen Schmerzen Means for drug treatment of acute and chronic pain |
| 01/08/2004 | DE10227508A1 Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Acid group-substituted Diphenylazetidinones, processes for their preparation, pharmaceutical compositions containing them and their use |
| 01/08/2004 | DE10227506A1 Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Ring-substituted Diphenylazetidinones, processes for their preparation, pharmaceutical compositions containing them and their use |
| 01/08/2004 | DE10226943A1 Phenylaminopyrimidine und ihre Verwendung Phenylaminopyrimidine and their use |
| 01/08/2004 | DE10226814A1 Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände New drug combinations for the treatment of ischemic conditions |
| 01/08/2004 | DE10226459A1 Verwendung von Dopamin-Partialagonisten zur Behandlung des Restless Legs Syndroms Use of dopamine partial agonists for the treatment of Restless Legs Syndrome |
| 01/08/2004 | DE10057290B4 Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten To be administered enterally supplement for parenteral nutrition or partial enteral / oral nutrition in critically ill patients, chronically ill and malnourished |
| 01/08/2004 | CA2844639A1 Method for the treatment of multiple sclerosis |
| 01/08/2004 | CA2744893A1 Aryl carbonyl derivatives as glucokinase activators |
| 01/08/2004 | CA2513143A1 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
| 01/08/2004 | CA2492066A1 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | CA2491549A1 Method of promoting smoking cessation |
| 01/08/2004 | CA2491427A1 Compositions and methods for therapeutic treatment |
| 01/08/2004 | CA2491156A1 Inhibitors of hcv ns5b polymerase |
| 01/08/2004 | CA2491034A1 Methods and materials for treating human papillomavirus infections |
| 01/08/2004 | CA2491002A1 Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
| 01/08/2004 | CA2490950A1 Inhibitors of hcv ns5b polymerase |
| 01/08/2004 | CA2490804A1 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| 01/08/2004 | CA2490411A1 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | CA2490367A1 Therapeutic methods for reducing fat deposition and treating associated conditions |
| 01/08/2004 | CA2490261A1 Differentiation modulating agents and uses therefor |
| 01/08/2004 | CA2490193A1 Glycoloyl-substituted oxazolidinone-derivatives as antibacterial agents |
| 01/08/2004 | CA2490138A1 Novel tetrahydropyridine derivatives as renin inhibitors |
| 01/08/2004 | CA2490130A1 Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor |
| 01/08/2004 | CA2490016A1 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| 01/08/2004 | CA2489552A1 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 01/08/2004 | CA2489376A1 Methods of organ regeneration |
| 01/08/2004 | CA2489090A1 Nutritional composition for detoxification and cancer prevention |
| 01/08/2004 | CA2488566A1 Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder |
| 01/08/2004 | CA2487824A1 Oncolytic viruses as phenotyping agents for neoplasms |
| 01/08/2004 | CA2487712A1 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 01/08/2004 | CA2482161A1 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| 01/07/2004 | EP1378509A1 Drugs containing triazaspiro 5.5]undecane derivatives as the active ingredient |
| 01/07/2004 | EP1378247A1 Visual function improving agents |
| 01/07/2004 | EP1378241A1 Pharmaceutical compositions comprising arsenic for the treatment of melanoma |
| 01/07/2004 | EP1378240A2 Pharmaceutical compositions comprising arsenic for the treatment of multiple myeloma |
| 01/07/2004 | EP1378177A1 Vitamin-containing system for stabilising the immune response of animals |